Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
This video presentation from the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute provides a concise 34-minute summary of essential prostate cancer clinical updates from GU ASCO 2025. Explore key findings including the TALAPRO-2 trial showing how Talazoparib plus Enzalutamide improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) with significant enrichment in the HRR population. Learn about the ENZA-P trial demonstrating how 177LuPSMA combined with Enzalutamide improves radiographic progression-free survival, overall survival, and quality of life in mCRPC patients. Discover insights from the WOLVERINE meta-analysis which confirms the benefits of metastasis-directed therapy in oligometastatic prostate cancer.
